CA2458371A1 — Glucagon-like peptide-1 analogs
Assigned to Eli Lilly and Co · Expires 2003-03-06 · 23y expired
What this patent protects
Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications a t one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27 , 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also d…
USPTO Abstract
Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications a t one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27 , 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.